ReviewBreast cancer research : BCR2026
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.
Lan Lei et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.